The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 10, 2010, Pages 1093-1098

  Hobson, Peter ^a   Meara, Jolyon ^a   Ishihara Paul, Lianna ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DETERMINATION; AGED; ARTICLE; COGNITIVE DEFECT; DEMENTIA; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; SURVIVAL; TIME OF DEATH; UNITED KINGDOM; COHORT ANALYSIS; ONSET AGE;

AGE OF ONSET; AGED; COHORT STUDIES; DEMENTIA; ENGLAND; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; PARKINSON DISEASE; SURVIVAL ANALYSIS; WALES;

EID: 77958135785     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.198689     Document Type: Article

References (55)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6.
2. Marras C, Lang A. Changing concepts in Parkinson's disease: moving beyond the decade of the brain. Neurology 2008;70:1996-2003.
3. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease. A community-based, prospective study. Neurology 2001;56:730-6.
4. Hobson JP, Meara RJ. The risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the UK. Mov Disord 2004;19:1043-9.
5. Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;26:837-44.
6. Pollock M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson's disease. Brain 1966;89:429-48.
7. Nobrega FT, Glattre E, Kurland LT, et al. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JR, eds. Progress in neurogenetics. Amsterdam: Excerpta Medica, 1967:477-85.
8. Hoehn M, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
9. Diamond SG, Markham CH, Treciokas LJ. Long-term experience with L-dopa: efficacy, progression, and mortality. In: Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Editiones Roche, 1976:444-5.
10. Zumstein H, Siegfried J. Mortality among Parkinson's patients treated with L-dopa combined with decarboxylase inhibitor. Eur Neurol 1976;14:321-7.
11. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's patients treated with sinemet. Adv Neurol 1979;24:489-97.
12. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-18.
13. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. QJM 1980;49:283-93.
14. Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 1983;19:253-64.
15. Marttila RJ, Rinne UK, Sonninen V. Levodopa in Parkinson's disease: effect on mortality. Acta Neurol Scand 1984;69:45-6.
16. Diamond SG, Markham CH, Hoehn MM. Multicenter study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
17. Di Rocco A, Molinari SP, Kollmeier B, et al. Parkinson's disease: progression and mortality in the L-dopa era. Adv Neurol 1996;69:3-11.
18. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-9.
19. Berger K, Bretler MMB, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000;54:S24-7. (Pubitemid 30390602)
20. Levy G, Tang M-X, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-13.
21. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson's disease in Olmsted County, Minnesota. Arch Neurol 2003;60:91-6. (Pubitemid 36078114)
22. Fall PA, Saleh A, Fredrickson M, et al. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-16. (Pubitemid 38263316)
23. Herlofson K, Atle Lie S, Aarsland D, et al. Mortality and Parkinson's disease: a community based study. Neurology 2004;62:937-42. (Pubitemid 38435782)
24. Hughes TA, Ross HF, Mindman RHS, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23.
25. de Lau LM, Schipper MA, Hofman A, et al. Prognosis of Parkinson's disease: risk of dementia and mortality: the Rotterdam study. Arc Neurology 2005;62:1265-9. (Pubitemid 41168354)
26. D'Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson's disease. A population-based study. J Neurol 2006;253:33-7. (Pubitemid 43157385)
27. Chen H, Zhang SM, Schwarzschild MA, et al. Survival of Parkinson's disease in a large prospective cohort of male health professionals. Mov Disord 2006;27:1002-7. (Pubitemid 44184603)
28. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson's disease: a 12-year population study. Neurology 2008:70:1017-22.
29. Diem-Zangerl A, Seppi K, Gregor K, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009;24:819-25.
30. Hely MA, Morris JGL, Reid WGJ, et al. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9.
31. Schrag A, Ben-Sholomo Y, Brown R, et al. Young onset Parkinson's disease-clinical features, natural history, and mortality. Mov Disord 1998;13:885-94.
32. Driver JA, Kurth T, Buring JE, et al. Parkinson's disease and risk of mortality. Neurology 2008;70:1423-30.
33. Ishihara LS, Cheesbrough A, Brayne C, et al. Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry 2007;78:1304-9. (Pubitemid 350221407)
34. Meara RJ, Bhowmick BK, Hobson JP. Accuracy of diagnosis in patients with presumed Parkinson's disease in a community based disease register. Age Ageing 1999;28:99-102.
35. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
36. Webster DD. Clinical analysis of the disability in Parkinson's disease. Mod Treat 1968;5:257-82.
37. Fahn S, Elton RL. Members of the UPDRS Development Committee: unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al, eds. Recent developments in Parkinson's disease. Florham Park: Macmillan Health Care Information, 1987:153-63.
38. Sheikh JI, Yesavage JA. Geriatric depression scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: a guide to assessment and intervention. New York: The Hawthorn Press, 1986:165-73.
39. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to elderly detection of dementia. Br J Psychiatry 1986;149:698-709. (Pubitemid 17205276)
40. Hobson JP, Edwards N, Meara RJ. The Parkinson's disease activities of daily living scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clin Rehabil 2001;15:241-6. (Pubitemid 32471882)
41. Williams A. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC, USA: American Psychiatric Association, 1994.
43. Haybittle JL. The use of the Gompertz function to relate changes in life expectancy to the standardized mortality ratio. Int J Epidemiol 1998;27:885-9.
44. Tsai SP, Hardy RJ, Wen CP. The standardized mortality ratio and life expectancy. Am J Epidemiol 1992;135:824-31.
45. Lai D, Hardy RJ, Tsai SP. Statistical analysis of the standardized mortality ratio and life expectancy. Am J Epidemiol 1996;143:832-40. (Pubitemid 26410967)
46. Pollard JH. Fun with Gompertz. Genus 1991;47:1-20.
47. Ebmeier KP, Calder SA, Crawford JR, et al. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study. Neurology 1990;40:1222-4.
48. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson disease. Arch Neurol 1997;54:260-4.
49. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New Eng J Med 1996;334:71-6.
50. Nussbaum M, Treves R, Inzelberg JM, et al. Survival in Parkinson's disease: the effect of dementia. Parkinsonism Relat Disord 1998;4:179-81. (Pubitemid 29183254)
51. Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002;8:CR241-6.
52. Hely MA, Morris JGL, Traficante R, et al. The Sydney multicenter study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-7. (Pubitemid 29392588)
53. Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000;55:1785-9. (Pubitemid 32103956)
54. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, et al. Long-term mortality results of the randomized controlled study comparing bromocripitine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 2001;16;511-14. (Pubitemid 36041157)
55. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease; thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64:87-93. (Pubitemid 40082942)